Overview
Compare with Ceribell, Inc., BIOLIFE SOLUTIONS INC or ViewRay, or pick any stock.
- TickerVASO on OTC2
- IndustryElectromedical & Electrotherapeutic Apparatus2
- HeadquartersPlainview, United States2
- Incorporated inDE3
- Business address137 Commercial Street, Ste. 200, Plainview, Ny 118033
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300O0FA66XDLHTH452
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
See how the biggest companies compare on our leaderboards
“future”, “intends”, the negative of these terms and similar expressions identify forward-looking statements.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Revenue Recognized At A Point In Time brought in 37% of the revenue VASO Corp broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Revenue Recognized At A Point In Time | $49.6M | $50.2M |
| Network Services | $38.4M | $39.3M |
| Revenue Recognized Over Time | $37.1M | $38.9M |
| Software Sales And Support | $4.6M | $3.2M |
| Medical Equipment Sales | $2.4M | $2.3M |
| Medical Equipment Service | $123.0K | $121.0K |
Business segments
Professional Sales Service Segments brought in 33% of the revenue VASO Corp broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Professional Sales Service Segments | $41.3M | $44.2M |
| Professional Sales Services | $41.3M | $44.2M |
| ITSegment | $43.0M | $42.5M |
| Equipment Segments | $2.5M | $2.4M |
| Equipments | $2.5M | $2.4M |
Regions
Domestic United States brought in 97% of the revenue VASO Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| Domestic United States | $84.7M | $86.7M |
| Non Domestic Foreign | $2.1M | $2.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue38¢$34.4M
- Research and development1¢$728.0K
- Selling, general and admin57¢$52.2M
- Income tax3¢$2.9M
- Profit2¢$1.6M
Out of $89.1M in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$9.3M
Out of $9.3M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $89.1M | $86.8M |
| Total cost of revenues | $34.4M | $34.7M |
| Gross profit | $54.7M | $52.0M |
| Selling, general and administrative | $52.2M | $49.0M |
| Research and development | $728.0K | $851.0K |
| Impairment of goodwill | $4.6M | |
| Business combination transaction costs | $1.9M | |
| Total operating expenses | $57.6M | $51.8M |
| Operating income (loss) | -$2.9M | $285.0K |
| Interest and financing costs | -$25.0K | -$4.0K |
| Interest and other income, net | $790.0K | $1.0M |
| Gain on sale of subsidiary | $827.0K | |
| Loss on disposal of fixed assets | -$7.0K | -$4.0K |
| Total other income, net | $1.6M | $992.0K |
| Income (loss) before income taxes | -$1.3M | $1.3M |
| Income tax benefit (expense) | $2.9M | -$326.0K |
| Net income | $1.6M | $951.0K |
| Foreign currency translation gain (loss) | $127.0K | -$138.0K |
| Comprehensive income | $1.7M | $813.0K |
| Income per common share basic (in Dollars per share) | $0.01 | $0.01 |
| Income per common share diluted (in Dollars per share) | $0.01 | $0.01 |
| Weighted average common shares outstanding basic (in Shares) | 175.8M shares | 175.4M shares |
| Weighted average common shares outstanding diluted (in Shares) | 176.0M shares | 175.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $35.0M | $26.3M | |
| Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $11,412 at December 31, 2025 and $10,708 at December 31, 2024 | $15.9M | $17.0M | |
| Inventories, net | $833.0K | $911.0K | |
| Deferred commission expense | $3.8M | $3.7M | |
| Prepaid expenses and other current assets | $2.0M | $2.4M | |
| Total current assets | $58.6M | $51.2M | |
| Property and equipment, net of accumulated depreciation of $9,131 at December 31, 2025 and $10,712 at December 31, 2024 | $1.3M | $1.5M | |
| Operating lease right of use assets | $1.5M | $2.3M | |
| Goodwill | $11.0M | $15.6M | $15.6M |
| Intangibles, net | $1.9M | $1.6M | |
| Other assets, net | $6.0M | $5.4M | |
| Investment in EECP Global | $135.0K | $436.0K | |
| Deferred tax assets, net | $8.0M | $4.9M | |
| Total assets | $88.3M | $82.9M | |
| Accounts payable | $4.0M | $4.2M | |
| Accrued commissions | $2.6M | $3.3M | |
| Accrued expenses and other liabilities | $9.2M | $8.3M | |
| Finance lease liabilities - current | $24.0K | ||
| Operating lease liabilities - current | $934.0K | $1.1M | |
| Sales tax payable | $779.0K | $802.0K | |
| Income taxes payable | $60.0K | ||
| Deferred revenue - current portion | $19.0M | $17.1M | |
| Notes payable - current portion | $286.0K | $6.0K | |
| Total current liabilities | $36.8M | $34.7M | |
| Operating lease liabilities, net of current portion | $591.0K | $1.3M | |
| Deferred revenue, net of current portion | $19.6M | $17.8M | |
| Other long-term liabilities | $1.9M | $1.4M | |
| Total long-term liabilities | $22.1M | $20.5M | |
| Common stock, $.001 par value; 250,000,000 shares authorized; 175,953,035 shares issued and outstanding at December 31, 2025 and 175,696,311 shares issued and outstanding at December 31, 2024 | $176.0K | $176.0K | |
| Additional paid-in capital | $62.1M | $62.0M | |
| Accumulated deficit | -$32.5M | -$34.1M | |
| Accumulated other comprehensive loss | -$315.0K | -$442.0K | |
| Total stockholders equity | $29.4M | $27.7M | $26.8M |
| Total liabilities and stockholders' equity | $88.3M | $82.9M | |
| Accounts and other receivables, net of an allowance for credit losses and commission adjustments | $11.4M | $10.7M | |
| Property and equipment, net of accumulated depreciation | $9.1M | $10.7M | |
| Preferred stock, par value (in Dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 250.0M shares | 250.0M shares | |
| Common Stock, shares issued (in Shares) | 176.0M shares | 175.7M shares | |
| Common Stock, shares outstanding (in Shares) | 176.0M shares | 175.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $35.0M | $26.3M | |
| Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $11,412 at December 31, 2025 and $10,708 at December 31, 2024 | $15.9M | $17.0M | |
| Inventories, net | $833.0K | $911.0K | |
| Deferred commission expense | $3.8M | $3.7M | |
| Prepaid expenses and other current assets | $2.0M | $2.4M | |
| Total current assets | $58.6M | $51.2M | |
| Property and equipment, net of accumulated depreciation of $9,131 at December 31, 2025 and $10,712 at December 31, 2024 | $1.3M | $1.5M | |
| Operating lease right of use assets | $1.5M | $2.3M | |
| Goodwill | $11.0M | $15.6M | $15.6M |
| Intangibles, net | $1.9M | $1.6M | |
| Other assets, net | $6.0M | $5.4M | |
| Investment in EECP Global | $135.0K | $436.0K | |
| Deferred tax assets, net | $8.0M | $4.9M | |
| Total assets | $88.3M | $82.9M | |
| Accounts payable | $4.0M | $4.2M | |
| Accrued commissions | $2.6M | $3.3M | |
| Accrued expenses and other liabilities | $9.2M | $8.3M | |
| Finance lease liabilities - current | $24.0K | ||
| Operating lease liabilities - current | $934.0K | $1.1M | |
| Sales tax payable | $779.0K | $802.0K | |
| Income taxes payable | $60.0K | ||
| Deferred revenue - current portion | $19.0M | $17.1M | |
| Notes payable - current portion | $286.0K | $6.0K | |
| Total current liabilities | $36.8M | $34.7M | |
| Operating lease liabilities, net of current portion | $591.0K | $1.3M | |
| Deferred revenue, net of current portion | $19.6M | $17.8M | |
| Other long-term liabilities | $1.9M | $1.4M | |
| Total long-term liabilities | $22.1M | $20.5M | |
| Common stock, $.001 par value; 250,000,000 shares authorized; 175,953,035 shares issued and outstanding at December 31, 2025 and 175,696,311 shares issued and outstanding at December 31, 2024 | $176.0K | $176.0K | |
| Additional paid-in capital | $62.1M | $62.0M | |
| Accumulated deficit | -$32.5M | -$34.1M | |
| Accumulated other comprehensive loss | -$315.0K | -$442.0K | |
| Total stockholders equity | $29.4M | $27.7M | $26.8M |
| Total liabilities and stockholders' equity | $88.3M | $82.9M | |
| Accounts and other receivables, net of an allowance for credit losses and commission adjustments | $11.4M | $10.7M | |
| Property and equipment, net of accumulated depreciation | $9.1M | $10.7M | |
| Preferred stock, par value (in Dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 250.0M shares | 250.0M shares | |
| Common Stock, shares issued (in Shares) | 176.0M shares | 175.7M shares | |
| Common Stock, shares outstanding (in Shares) | 176.0M shares | 175.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $1.6M | $951.0K |
| Depreciation and amortization | $858.0K | $824.0K |
| Deferred income taxes | -$3.0M | $51.0K |
| Loss from investment in EECP Global | $408.0K | $247.0K |
| Gain on sale of subsidiary | -$827.0K | |
| Impairment of goodwill | $4.6M | |
| Provision for credit losses and commission adjustments | $813.0K | $777.0K |
| Write-off of Achari loan | $573.0K | |
| Share-based compensation | $33.0K | $54.0K |
| Accounts and other receivables | $925.0K | -$5.1M |
| Due from related parties | -$494.0K | -$365.0K |
| Inventories | $86.0K | $574.0K |
| Deferred commission expense | -$171.0K | -$373.0K |
| Prepaid expenses and other current assets | -$380.0K | -$474.0K |
| Other assets, net | -$777.0K | -$524.0K |
| Accounts payable | $600.0K | $1.5M |
| Accrued commissions | -$541.0K | $832.0K |
| Accrued expenses and other liabilities | $1.5M | $921.0K |
| Sales tax payable | -$4.0K | $106.0K |
| Income taxes payable | -$60.0K | $56.0K |
| Deferred revenue | $3.7M | $2.7M |
| Other long-term liabilities | $490.0K | -$89.0K |
| Net cash provided by operating activities | $9.3M | $3.3M |
| Purchases of equipment and software | -$925.0K | -$1.5M |
| Loan to Achari | -$573.0K | |
| Redemption of short-term investments | $13.8M | |
| Proceeds from sale of VasoHealthcare IT Corp. | $200.0K | |
| Net cash (used in) provided by investing activities | -$725.0K | $11.7M |
| Payroll taxes paid by withholding shares | -$1.0K | -$8.0K |
| Proceeds from note payable | $3.6M | |
| Repayment of notes payable and finance lease obligations | -$3.4M | -$81.0K |
| Net cash provided by (used in) financing activities | $248.0K | -$89.0K |
| Effect of exchange rate differences on cash and cash equivalents | -$17.0K | $7.0K |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | $8.8M | $14.9M |
| Interest paid | $26.0K | $4.0K |
| Income taxes paid | $230.0K | $183.0K |
| Initial recognition of operating lease right of use asset and liability | $185.0K | $1.4M |
| Transfer of fixed assets to inventory | $261.0K |
No quarter-by-quarter statement was filed.
Corporate structure
VASO Corp sits at the top of its group. 9 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of VASO Corp
- Jun Ma Filed SCHEDULE 13D on VASO Corp, latest Apr 16, 2026
- Joshua Markowitz Filed SCHEDULE 13D on VASO Corp, latest Apr 10, 2026
- VASO Corp Plainview, New York, United States
- EECP Global Corporation Subsidiary · New York, United States
- Fast Growth Enterprises Limited Subsidiary · British Virgin Islands
- NetWolves Network Services LLC Subsidiary · Florida, United States
- Vaso Diagnostics, Inc. Subsidiary · New York, United States
- Vasomedical Global Corp. Subsidiary · New York, United States
- Vasomedical Solutions, Inc. Subsidiary · New York, United States
- VasoMedical, Inc. Subsidiary · Delaware, United States
- VasoTechnology, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What VASO Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $10.4M6 Dec 31, 2025 | $12.3M6 Dec 31, 2024 | −15.2% |
| Accumulated depreciation | $9.1M6 Dec 31, 2025 | $10.7M6 Dec 31, 2024 | −14.8% |
| Property and equipment, net | $1.3M6 Dec 31, 2025 | $1.5M6 Dec 31, 2024 | −18.2% |
| Operating-lease assets (leased space) | $1.5M6 Dec 31, 2025 | $2.3M6 Dec 31, 2024 | −35.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $35.0M6 Dec 31, 2025 | $26.3M6 Dec 31, 2024 | +33.4% |
| Stakes in other companies (equity method) | $135.0K6 Dec 31, 2025 | $436.0K6 Dec 31, 2024 | −69.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $11.0M6 Dec 31, 2025 | $15.6M6 Dec 31, 2024 | −29.5% |
| Intangible assets, net (excluding goodwill) | $1.9M6 Dec 31, 2025 | $1.6M6 Dec 31, 2024 | +19.8% |
| Finite-lived intangibles, net | $1.8M6 Dec 31, 2025 | $1.4M10 Dec 31, 2024 | +28.4% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $833.0K6 Dec 31, 2025 | $911.0K6 Dec 31, 2024 | −8.6% |
| Raw materials | $492.0K6 Dec 31, 2025 | $596.0K6 Dec 31, 2024 | −17.4% |
| Work in process | $57.0K6 Dec 31, 2025 | $12.0K6 Dec 31, 2024 | +375.0% |
| Finished goods | $284.0K6 Dec 31, 2025 | $303.0K6 Dec 31, 2024 | −6.3% |
Properties, in its own words
The Company houses its headquarters and domestic medical device operations at an 8,700 square foot facility located at 137 Commercial Street, Plainview, New York 11803, under a lease with a term that expires on September 30, 2028 and with a base annual rental of approximately $85,000. The Company’s NetWolves unit leases a 16,200 square foot facility in Tampa, Florida, under a lease expiring in June 2027 with an annual rental of approximately $240,000. We believe that our current facilities are adequate for foreseeable current and future needs.
We lease our office, engineering and production facilities in China. Specifically, we lease approximately 14,700 square feet of space in Wuxi, China under leases expiring in August 2026, September 2026, and December 2026 at an aggregate annual cost of approximately $75,000. Such leases are renewable upon expiration. We also lease office space of approximately 1,700 square feet to host our software R&D team in Tianjin, China under a lease expiring in February 2028 at an annual cost of approximately $23,000.
Item 2 of the 10-K filed Mar 31, 2026.5
Leadership
Who has led VASO Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerGlover Thomas Apr 6, 2006 to Apr 6, 200614
- PresidentGlover Thomas Apr 6, 2006 to Apr 6, 200614
- Chief financial officerMichael Beecher Sep 26, 2011 to Mar 22, 201815
- Chief financial officerJonathan P. Newton Sep 10, 2010 to Dec 30, 201916
- Chief financial officerDavid Tarachand Singh Mar 16, 2009 to Mar 16, 200917
- Chief financial officerThomas W. Fry Apr 6, 2006 to Apr 6, 200618
- Chief financial officerTricia Efstathiou Sep 29, 2006 to Sep 29, 200619
- Chief operating officerPeter C. Castle Jun 16, 2015 to Mar 22, 201820
Board members and other officers (18)
- Senior Vice PresidentNelson Randall Hill Jul 31, 2012 to Jul 6, 201621
- Vice Pres.Finance & ControllerJonathan P. Newton Nov 15, 2011 to Apr 19, 201822
- Board memberShaun D. McMeans Jul 29, 2026 to now23
- Board memberLeon Dembo Apr 3, 2023 to Nov 19, 202424
- Board memberJaney Moen Apr 7, 2020 to Mar 11, 202125
- Board memberJoshua Markowitz Jun 22, 2015 to Dec 11, 202326
- Board memberNelson Randall Hill Apr 22, 2013 to Feb 10, 201427
- Board memberDavid H. Lieberman Mar 10, 2011 to Jul 6, 201628
- Board memberEdgar Rios Mar 10, 2011 to Jul 6, 201629
- Board memberWilliam Edward Dempsey Jul 15, 2010 to Mar 1, 201130
- Board memberPeter C. Castle Aug 25, 2010 to Mar 22, 201831
- Board memberSimon Srybnik Jun 25, 2007 to Jul 6, 201632
- Board memberBehnam Movaseghi Jul 20, 2007 to Jul 6, 201633
- Board memberDerek Enlander Jul 26, 2007 to Sep 10, 201034
- Board memberPhotios T. Paulson Nov 30, 2007 to Apr 27, 201035
- Board memberJoseph Giacalone Dec 11, 2007 to Oct 22, 200836
- Board memberGlover Thomas Apr 6, 2006 to Apr 6, 200614
- Board memberMartin Zeiger Oct 11, 2006 to Apr 27, 201037
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- EECP Global Corporation New York4
- Fast Growth Enterprises Limited British Virgin Islands4
- NetWolves Network Services LLC Florida4
- Vaso Diagnostics, Inc. New York4
- VasoMedical, Inc. Delaware4
- VasoTechnology, Inc. Delaware4
- Vasomedical Global Corp. New York4
- Vasomedical Solutions, Inc. New York4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Aug 6, 20268-K Financial statements and exhibits38
- Jul 31, 20268-K Entered a material agreement; Completed an acquisition or sale39
- Jul 23, 20268-K Executive or director change40
- May 8, 20268-K Executive or director change41
- Feb 12, 20268-K Bylaws or fiscal year changed42
- Dec 19, 20258-K Shareholder vote43
- Nov 20, 20258-K Other events44
- Jan 3, 20258-K Executive or director change45
- Sep 19, 20248-K Ended a material agreement; Other events46
- Sep 10, 20248-K Shareholder vote; Other events47
- Aug 28, 20248-K Other events48
- Aug 23, 20248-K Other events49
- Apr 6, 2006New chief executive Glover Thomas becomes CEO14
Filings
55 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 15 major events, 5 insider forms, 2 large holders, 13 other. The latest 20:
- Aug 14, 202610-Q QUARTERLY REPORT EDGAR
- Aug 6, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
- Jul 31, 20268-K CURRENT REPORT EDGAR
- Jul 29, 20263 EDGAR
- Jul 23, 20268-K CURRENT REPORT EDGAR
- May 15, 202610-Q QUARTERLY REPORT EDGAR
- May 8, 20268-K CURRENT REPORT EDGAR
- Apr 16, 2026SCHEDULE 13D EDGAR
- Apr 10, 2026SCHEDULE 13D EDGAR
- Mar 31, 202610-K ANNUAL REPORT EDGAR
- Feb 12, 20268-K CURRENT REPORT EDGAR
- Dec 19, 20258-K CURRENT REPORT EDGAR
- Nov 26, 2025DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Nov 20, 20258-K CURRENT REPORT EDGAR
- Nov 14, 202510-Q QUARTERLY REPORT EDGAR
- Nov 5, 2025DEF 14A PROXY STATEMENT EDGAR
- Aug 14, 202510-Q QUARTERLY REPORT EDGAR
- May 15, 202510-Q QUARTERLY REPORT EDGAR
- Mar 31, 202510-K ANNUAL REPORT EDGAR
- Jan 3, 20258-K CURRENT REPORT EDGAR
The 55 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | Ma JunChief Exec Officer & President | Buy | 200,000 | $0.13 | $26.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Jun MaSCHEDULE 13D, 1 filing Apr 16, 202650
- Joshua MarkowitzSCHEDULE 13D, 1 filing Apr 10, 202651
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Vima LLC | 200 | $38 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How VASO Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVASO Corp1
- CIK0000839087
- Employer ID (EIN)11-28714345
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address137 Commercial Street, Ste. 200, Plainview, NY 118031
- Phone516-997-46001
- Shares outstanding176,018,035 as of Aug 12, 202613
- Public float$12.8M as of Jun 30, 20255
- AuditorUHY LLP, Sterling Heights, Michigan PCAOB ID 1195; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceSep 1, 19951
- Filings506 in all: 4 (129), 8-K (92), 10-Q (89), 10-K (27), DEF 14A (25), 3 (21), UPLOAD (16), 10-K/A (10)1
All 39 form types
4/A (10), CORRESP (10), 8-K/A (8), S-8 (8), NT 10-Q (6), 10QSB (5), DEFA14A (5), S-3 (5), 10-Q/A (3), 425 (3), NT 10-K (3), PRE 14A (3), 10KSB (2), 10KSB/A (2), 3/A (2), 424B3 (2), PRER14A (2), S-3/A (2), SC 13D/A (2), SC 13G/A (2), SCHEDULE 13D (2), 10-KT (1), 10KSB40 (1), 424B2 (1), ARS (1), CT ORDER (1), POS AM (1), PREM14A (1), REGDEX (1), SC 13D (1), SC 13G (1)
- Latest filingsAnnual report (10-K) Mar 31, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Nov 5, 2025
Latest 8-K (8-K) Jul 31, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| N/A | NONE |
From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks VASO Corp names in Item 1A of its 10-K filed Mar 31, 2026: 3 risks under these headings, as written.5
- We have foreign operations and are subject to the associated risks of doing business in foreign countries.
- We depend on several suppliers for the supply of certain products.
- Our growth could suffer if the markets into which we sell products decline, do not grow as anticipated or experience cyclicality.
- Anti-takeover Risk Factor
Legal proceedings
The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee-related matters, incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARVASO Corp filings on SEC EDGAR
- 2
- 3SEC EDGARVASO Corp filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARVASO Corp 10-K for fiscal 2025
- 7SEC EDGARVASO Corp 10-K for fiscal 2019
- 8SEC EDGARVASO Corp 10-K for fiscal 2020
- 9SEC EDGARVASO Corp 10-K for fiscal 2022
- 10SEC EDGARVASO Corp 10-K for fiscal 2023
- 11SEC EDGARVASO Corp 10-K for fiscal 2021
- 12SEC EDGARVASO Corp 10-Q for fiscal 2026
- 13SEC EDGARVASO Corp 10-Q for fiscal 2026
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARShaun D. McMeans, Board member
- 24SEC EDGARLeon Dembo, Board member
- 25SEC EDGARJaney Moen, Board member
- 26SEC EDGARJoshua Markowitz, Board member
- 27SEC EDGARNelson Randall Hill, Board member
- 28SEC EDGARDavid H. Lieberman, Board member
- 29SEC EDGAREdgar Rios, Board member
- 30SEC EDGARWilliam Edward Dempsey, Board member
- 31SEC EDGARPeter C. Castle, Board member
- 32SEC EDGARSimon Srybnik, Board member
- 33SEC EDGARBehnam Movaseghi, Board member
- 34SEC EDGARDerek Enlander, Board member
- 35SEC EDGARPhotios T. Paulson, Board member
- 36SEC EDGARJoseph Giacalone, Board member
- 37SEC EDGARMartin Zeiger, Board member
- 38SEC EDGARFinancial statements and exhibits
- 39
- 40SEC EDGARExecutive or director change
- 41SEC EDGARExecutive or director change
- 42SEC EDGARBylaws or fiscal year changed
- 43SEC EDGARShareholder vote
- 44SEC EDGAROther events
- 45SEC EDGARExecutive or director change
- 46
- 47SEC EDGARShareholder vote; Other events
- 48SEC EDGAROther events
- 49SEC EDGAROther events
- 50SEC EDGARJun Ma SCHEDULE 13D on VASO Corp
- 51
- 52